Krystal Biotech, Inc.

What they do

Krystal develops genetic medicines using a patented engineered herpes simplex virus-1 (HSV-1) vector platform that delivers therapeutic transgenes without integrating into host DNA. Its first commercial product, VYJUVEK, is a topical, redosable gene therapy approved in the United States, EU, UK, and Japan for dystrophic epidermolysis bullosa (DEB), delivering two copies of the COL7A1 gene to DEB wounds. The company manufactures at two in-house CGMP facilities and also operates wholly-owned subsidiary Jeune Aesthetics, which is exploring aesthetic uses of the platform.

Revenue drivers

• VYJUVEK - United States — Primary revenue source: global net product revenue was $119.2M in Q2 2026, with the U.S. being the largest market, supported by over 730 reimbursement approvals and more than 640 unique prescribers as of the end of Q2 2026.
• VYJUVEK - International — Launched in Germany, France, and Japan in 2025, with pricing discussions ongoing; launches in Spain and Italy are expected before year end 2026, and pricing talks are underway in the UK.
• Pipeline candidates — KB803 (corneal abrasions in DEB), KB801 (neurotrophic keratitis), and KB407 (cystic fibrosis) are in registrational or clinical studies and generate no revenue today.

Recent performance

Second quarter 2026 global VYJUVEK net product revenue was $119.2 million, up 24% versus the prior-year quarter, with gross margin of 95%. Cumulative VYJUVEK revenue since launch reached $965.9 million. The company ended the quarter with $1.1 billion in cash and investments. Quarterly revenue has grown sequentially from $97.8 million in Q3 2025 to $107.1 million in Q4 2025, $116.4 million in Q1 2026, and $119.2 million in Q2 2026.

Strategy

The company is expanding VYJUVEK globally, pursuing pricing and reimbursement in European markets and planning additional marketing authorization filings in Switzerland and Australia in 2H 2026. Internationally, it is driving physician engagement and patient starts in Germany, France, and Japan, with launches in Spain and Italy expected before year end. R&D is focused on registrational readouts across eye, lung, and skin programs, including KB803, KB801, and KB407. Management describes the next 12 to 18 months as a potential transition to a multi-product genetic medicines company.

Risks

• Dependence on VYJUVEK — Krystal's near-term prospects and revenue are substantially dependent on VYJUVEK, which is the only commercial product and had no revenue before 2023.
• International pricing and reimbursement — German and French pricing discussions remain ongoing, expected until at least 2H 2026 in Germany and into 2027 in France, which could delay or limit international revenue.
• Pipeline development risk — KB803, KB801, and KB407 are clinical-stage and may fail to generate data supporting approval, with KB803 top-line data expected in Q4 2026 and KB801 enrollment targeted for completion before year end.
• Regulatory approvals outside current markets — VYJUVEK is approved in the U.S., EU, UK, and Japan, but the company states it can provide no assurances of approval in any other jurisdiction.

Outlook

Management expects multiple clinical data readouts in 2H 2026, including top-line KB803 data in Q4 2026 and completion of KB801 enrollment before year end. VYJUVEK launches in Spain and Italy are expected before year end 2026, with marketing authorization filings planned in Switzerland and Australia. The company frames the next 12 to 18 months as a potential transition from a commercial success story to a multi-product genetic medicines company.